AI-generated summary
This review describes transcranial photobiomodulation, a light therapy applied to the scalp, forehead or intranasally, and summarizes experimental and clinical studies in Alzheimer's disease, Parkinson's disease and brain stroke. The authors report that safety and potential efficacy have been indicated in some central nervous system diseases. They conclude the evidence base is still insufficient, though tPBM may be promising as adjuvant therapy.
- Who or what was studied
- Patients with Alzheimer's disease, Parkinson's disease, or brain stroke, and experimental models; the abstract does not state the number of studies or participants.
- Limits stated in the abstract
- The authors state that the evidence base regarding efficacy in neurodegenerative and vascular brain diseases is still insufficient.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on mediasphera.ru.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Photobiomodulation, Stroke. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.